Some members of Congress are considering a drug pricing plan – H.R. 3 – that could have devastating impacts on American patients, jobs and medical innovation. It relies on a form of price setting in which the U.S. government would determine the value of life-saving medicines based on decisions by foreign governments about which medicines are worth investing in and which ones are not – regardless of what patients and their doctors think.